Citadel Advisors’s Achillion Pharmaceuticals ACHN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q4 | – | Sell |
-33,300
| Closed | -$120K | – | 10131 |
|
|
2019
Q3 | $120K | Buy |
33,300
+6,900
| +26% | +$26.6K | ﹤0.01% | 8399 |
|
|
2019
Q2 | $71K | Sell |
26,400
-11,100
| -30% | -$32.8K | ﹤0.01% | 8638 |
|
|
2019
Q1 | $111K | Buy |
37,500
+15,900
| +74% | +$39.1K | ﹤0.01% | 8510 |
|
|
2018
Q4 | $34K | Buy |
21,600
+8,300
| +62% | +$23.5K | ﹤0.01% | 8589 |
|
|
2018
Q3 | $49K | Buy |
+13,300
| New | +$39.6K | ﹤0.01% | 8812 |
|
|
2018
Q2 | – | Sell |
-35,500
| Closed | -$132K | – | 9524 |
|
|
2018
Q1 | $132K | Buy |
35,500
+23,100
| +186% | +$75.6K | ﹤0.01% | 7606 |
|
|
2017
Q4 | $36K | Sell |
12,400
-3,700
| -23% | -$13.4K | ﹤0.01% | 7731 |
|
|
2017
Q3 | $72K | Buy |
16,100
+5,900
| +58% | +$26.2K | ﹤0.01% | 7115 |
|
|
2017
Q2 | $47K | Sell |
10,200
-4,600
| -31% | -$18.5K | ﹤0.01% | 7109 |
|
|
2017
Q1 | $62K | Buy |
14,800
+4,600
| +45% | +$19.1K | ﹤0.01% | 6998 |
|
|
2016
Q4 | $42K | Sell |
10,200
-29,000
| -74% | -$154K | ﹤0.01% | 6909 |
|
|
2016
Q3 | $318K | Sell |
39,200
-1,200
| -3% | -$10.2K | ﹤0.01% | 5584 |
|
|
2016
Q2 | $315K | Buy |
40,400
+5,600
| +16% | +$48K | ﹤0.01% | 5135 |
|
|
2016
Q1 | $269K | Buy |
34,800
+10,700
| +44% | +$78.4K | ﹤0.01% | 5241 |
|
|
2015
Q4 | $260K | Sell |
24,100
-3,500
| -13% | -$31.8K | ﹤0.01% | 5435 |
|
|
2015
Q3 | $191K | Sell |
27,600
-23,300
| -46% | -$190K | ﹤0.01% | 6215 |
|
|
2015
Q2 | $451K | Buy |
50,900
+2,500
| +5% | +$23.6K | ﹤0.01% | 5147 |
|
|
2015
Q1 | $477K | Sell |
48,400
-103,200
| -68% | -$1.29M | ﹤0.01% | 4977 |
|
|
2014
Q4 | $1.86M | Buy |
151,600
+74,600
| +97% | +$911K | ﹤0.01% | 2995 |
|
|
2014
Q3 | $768K | Buy |
77,000
+11,500
| +18% | +$107K | ﹤0.01% | 4055 |
|
|
2014
Q2 | $496K | Buy |
65,500
+25,900
| +65% | +$103K | ﹤0.01% | 4402 |
|
|
2014
Q1 | $130K | Buy |
39,600
+1,700
| +4% | +$5.95K | ﹤0.01% | 5935 |
|
|
2013
Q4 | $126K | Sell |
37,900
-17,500
| -32% | -$50.8K | ﹤0.01% | 5429 |
|
|
2013
Q3 | $167K | Buy |
55,400
+50,500
| +1,031% | +$346K | ﹤0.01% | 4933 |
|
|
2013
Q2 | $40K | Buy |
+4,900
| New | +$37.4K | ﹤0.01% | 5778 |
|
Citadel Advisors's ACHN Position: Q1 2020 in Review
Citadel Advisors sold out of Achillion Pharmaceuticals (ACHN) in Q1 2020, closing a stake of 51,221 shares — an estimated $309K sold.
Citadel Advisors first reported a position in ACHN in Q2 2013 and held it in 27 quarters. The position peaked at $15.4M in Q3 2018. 0 funds tracked by Wall St. Rank hold ACHN as of Q1 2020.
- Citadel Advisors reported no remaining Achillion Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
- Citadel Advisors sold 51,221 Achillion Pharmaceuticals shares in Q1 2020, an estimated $309K.
- Citadel Advisors first reported a position in Achillion Pharmaceuticals in Q2 2013 and held it in 27 quarters.
- Citadel Advisors's Achillion Pharmaceuticals position peaked at $15.4M in Q3 2018.
- 0 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q1 2020.
Based on Citadel Advisors's 13F filing for Q1 2020, filed 15 May 2020.